GlassScriptPhysician profile
Brandon J Coakley
NPI 1992065858
$23,841.83
in general payments reported to CMS, 2019-2025
34 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 76% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $79.47 · 2021: $825 · 2022: $684 · 2023: $2,563 · 2024: $859 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761 · Consulting Fee: $1,419 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.17 |
| Consulting Fee | $1,419.00 |
| Education | $364.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,429.41 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $2,248.58 | 2021-2025 | Libtayo, Dupixent |
| Organogenesis INC. | $625.22 | 2021-2025 | Puraply, Novachor, Affinity |
| Sun Pharmaceutical Industries INC. | $547.57 | 2021-2025 | Ilumya |
| Genzyme Corporation | $286.38 | 2021-2025 | |
| Genentech USA, INC. | $261.11 | 2019-2022 | |
| Janssen Biotech, INC. | $240.58 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $218.83 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $161.52 | 2021-2025 | |
| Allergan, INC. | $128.45 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.57 | 2023 | Sotyktu |
| Amgen INC. | $54.90 | 2022-2024 | Otezla |
| Leo Pharma INC. | $52.27 | 2019-2023 | Adbry |
| Pfizer INC. | $50.08 | 2021 | |
| Biofrontera INC. | $44.84 | 2020-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $38.60 | 2021-2023 | Valchlor |
| Kerecis Limited | $35.69 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.13 | 2021-2024 | Siliq, Duobrii, Targretin |
| Incyte Corporation | $31.47 | 2021-2023 | Opzelura |
| Lilly USA, LLC | $28.05 | 2021-2025 | Ebglyss, Taltz |
| Journey Medical Corporation | $24.48 | 2022 | |
| Tempus Ai, INC | $24.45 | 2024 | |
| Convatec INC. | $23.92 | 2023 | |
| Smith+Nephew, INC. | $21.16 | 2023 | Grafix Pl |
| Botanix Sb INC | $21.08 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.81 | 2023 | Spevigo |
| Integra Lifesciences Corporation | $16.30 | 2019 | |
| Mayne Pharma Commercial LLC | $14.95 | 2022 | |
| Galderma Laboratories, L.P. | $14.66 | 2021 | |
| Arcutis Biotherapeutics, INC. | $13.79 | 2024 | Zoryve |
| Misonix INC | $13.19 | 2021 | |
| Celgene Corporation | $11.79 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Coakley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.